{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:12:00Z","timestamp":1792023120535,"version":"4.4.0"},"reference-count":40,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop machine learning (ML) models to predict the probability at baseline of achieving low disease activity (LDA) and high health-related quality of life (HRQOL) in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with secukinumab (SEC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AQUILA is an ongoing multicenter, prospective, noninterventional study assessing the effectiveness and safety of SEC in patients with active PsA or axSpA in Germany. Data from 1961 participants were used to develop ML models for predicting treatment outcomes. We investigated baseline prediction of achieving LDA and high HRQOL at week 16 using binary ML algorithms, identifying main predictors for LDA and high HRQOL and their direction of influence. In addition, explainable artificial intelligence (XAI) estimated the importance and impact of each predictor based on how it affected the change in individual patient predictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In PsA, the main LDA predictors were patient global assessment, physician global assessment, pretreatment with biologic disease-modifying antirheumatic drugs (bDMARDs), tender joint count (TJC), and age; high HRQOL predictors were PsA Impact of Disease, Beck Depression Inventory (BDI), height, TJC, and BMI (kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). In axSpA, the main LDA predictors were Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pretreatment with bDMARDs, C-reactive protein, Assessment of SpondyloArthritis international Society Health Index (ASAS HI), and height; high HRQOL predictors were ASAS HI, BDI, BMI, height, and age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>XAI provides significant value by enabling explanations of individual patient predictions and their visualizations. This modeling approach may help in the development of a clinical decision support system for patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0327","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:20:12Z","timestamp":1760530812000},"page":"152-161","source":"Crossref","is-referenced-by-count":5,"title":["Predicting Treatment Outcomes in Patients With Psoriatic Arthritis or Axial Spondyloarthritis: An Artificial Intelligence\u2013Driven Approach"],"prefix":"10.3899","volume":"53","author":[{"given":"Asmir","family":"Voden\u010darevi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Brandt-Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"B\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00e4stner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-5574","authenticated-orcid":false,"given":"Michaela","family":"K\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Glassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peterlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026070105051072000_53.2.152.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214065"},{"key":"2026070105051072000_53.2.152.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2026070105051072000_53.2.152.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4447"},{"key":"2026070105051072000_53.2.152.4","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"2026070105051072000_53.2.152.5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review","volume":"14","author":"Kotsis","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026070105051072000_53.2.152.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0006-8"},{"key":"2026070105051072000_53.2.152.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2026070105051072000_53.2.152.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2026070105051072000_53.2.152.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.514"},{"key":"2026070105051072000_53.2.152.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2026070105051072000_53.2.152.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2026070105051072000_53.2.152.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002939"},{"key":"2026070105051072000_53.2.152.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2026070105051072000_53.2.152.14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026070105051072000_53.2.152.15","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","article-title":"Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Cruz-Machado","year":"2020","journal-title":"Rheumatology"},{"key":"2026070105051072000_53.2.152.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170449"},{"key":"2026070105051072000_53.2.152.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152078"},{"key":"2026070105051072000_53.2.152.18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/1744666X.2015.1052795","article-title":"Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes","volume":"11","author":"Braun","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"2026070105051072000_53.2.152.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2026070105051072000_53.2.152.20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40265-021-01476-3","article-title":"Secukinumab: a review in psoriatic arthritis","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"2026070105051072000_53.2.152.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02567-y"},{"key":"2026070105051072000_53.2.152.22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13075-021-02635-3","article-title":"Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"23","author":"Lee","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026070105051072000_53.2.152.23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13075-021-02439-5","article-title":"Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs","volume":"23","author":"Voden\u010darevi\u0107","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026070105051072000_53.2.152.24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-022-02838-2","article-title":"Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning","volume":"24","author":"Queiro","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026070105051072000_53.2.152.25","doi-asserted-by":"crossref","first-page":"891863","DOI":"10.3389\/fmed.2022.891863","article-title":"Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning","volume":"9","author":"Queiro","year":"2022","journal-title":"Front Med"},{"key":"2026070105051072000_53.2.152.26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/jcm12030931","article-title":"Moderate-high disease activity in patients with recent-onset psoriatic arthritis-multivariable prediction model based on machine learning","volume":"12","author":"Queiro","year":"2023","journal-title":"J Clin Med"},{"key":"2026070105051072000_53.2.152.27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/acr2.11499","article-title":"Machine learning applied to patient-reported outcomes to classify physician-derived measures of rheumatoid arthritis disease activity","volume":"4","author":"Curtis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026070105051072000_53.2.152.28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1874312901913010053","article-title":"Baseline characteristics of patients with ankylosing spondylitis and psoriatic arthritis treated with secukinumab in the real-world setting: AQUILA, a non-interventional study","volume":"13","author":"Kiltz","year":"2019","journal-title":"Open Rheumatol J"},{"key":"2026070105051072000_53.2.152.29","unstructured":"G\u00e9ron A. Hands-on machine learning with Scikit-Learn, Keras and TensorFlow: concepts, tools, and techniques to build intelligent systems, second edition. Sebastopol: O\u2019Reilly Media; 2019."},{"key":"2026070105051072000_53.2.152.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpc.2010.04.018"},{"key":"2026070105051072000_53.2.152.31","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010920819831"},{"key":"2026070105051072000_53.2.152.32","doi-asserted-by":"publisher","DOI":"10.4103\/tjem.tjem_182_23"},{"key":"2026070105051072000_53.2.152.33","unstructured":"Lundberg S , Lee SI. A unified approach to interpreting model predictions. In: NIPS\u201917: Proceedings of the 31st International Conference on Neural Information Processing Systems. Adv Neural Inf Process Syst 2017; 4768-4777."},{"key":"2026070105051072000_53.2.152.34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Jt Bone Spine"},{"key":"2026070105051072000_53.2.152.35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s42358-023-00295-2","article-title":"Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort","volume":"63","author":"Molica Colella","year":"2023","journal-title":"Adv Rheumatol"},{"key":"2026070105051072000_53.2.152.36","doi-asserted-by":"crossref","first-page":"103357","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026070105051072000_53.2.152.37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.22141\/pjs.13.4.2023.391","article-title":"Prevalence of overweight and obesity, and associated risk factors in an axial spondyloarthritis cohort","volume":"13","author":"Protsenko","year":"2024","journal-title":"Pain Joints Spine"},{"key":"2026070105051072000_53.2.152.38","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1136\/annrheumdis-2019-eular.5994","article-title":"AB0734 Changes in height and body mass index over time in patients with axial spondyloarthritis, treated with tumor necrosis factor-a inhibitors [abstract]","volume":"78","author":"Vasilenko","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026070105051072000_53.2.152.39","unstructured":"Gauch HG. Scientific method in practice. Cambridge: Cambridge University Press; 2003."},{"key":"2026070105051072000_53.2.152.40","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences, second edition. Mahwah: Lawrence Erlbaum Associates; 1988."}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:13:50Z","timestamp":1782908030000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3899\/jrheum.2025-0327"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0327","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}